Population pharmacokinetics and dose evaluation for second-line TB drugs in patients with diabetes.

• Tác giả: H Cao, J Cao, L Davies Forsman, S Dong, Y Hu, X Li, Z Ning, G Shao, S Wang, H Zhong
• Ngôn ngữ: eng
• Ký hiệu phân loại: 004.338 Systems analysis and design, computer architecture, performance evaluation of real-time computers
• Thông tin xuất bản: France : The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease , 2025
• Bộ sưu tập: NCBI
• ID: 742345

Tóm tắt

 <
 sec>
 <
 title>
 BACKGROUND<
 /title>
 To evaluate currently recommended dosage using the population pharmacokinetics (PK) of bedaquiline (BDQ), clofazimine, cycloserine, linezolid (LZD) and moxifloxacin (MFX) in patients with multidrug-resistant TB (MDR-TB) and type II diabetes mellitus (DM).<
 /sec>
 <
 sec>
 <
 title>
 METHODS<
 /title>
 A prospective multi-centre PK study was conducted in China between 2016 and 2019. Population PK models were developed using nonlinear mixed-effect analyses based on the blood samples collected by rich sampling. The probability of target attainment (PTA) analysis was estimated using the Monte Carlo simulation.<
 /sec>
 <
 sec>
 <
 title>
 RESULTS<
 /title>
 A total of 1,450 plasma samples were collected from 58 participants with DM. Simulations showed that the WHO-recommended regimens of LZD (600 mg daily) and MFX (400 mg daily) achieved >
  90% PTA for